Deuterium-enriched risperidone

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

A deuterium-enriched compound, wherein the compound is selected from:

• or a pharmaceutically acceptable salt, wherein when one of R1-R27 is present, it is selected from H or D.

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

(canceled)

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof.

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof, wherein R1-8 and R12-27 are selected from H and D.

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof, wherein R1-15 and R25-27 are selected from H and D.

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof, wherein R1-24 are selected from H and D.

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof, wherein R1-24 are selected from H and D.

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof.

A deuterium-enriched compound, wherein the compound is:

• or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition, comprising:

• a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one compound selected from:
• or a pharmaceutically acceptable salt form thereof.

A method for treating schizophrenia comprising:

• administering, to a patient in need thereof, a therapeutically effective amount of a compound selected from:
• or a pharmaceutically acceptable salt form thereof.